Mediwound announces positive topline results from its u.s. phase 2 trial of escharex for debridement of chronic wounds

Primary endpoint met with highly statistically significant results no observed safety issues final data r eadout expected in second quarter of 2022
MDWD Ratings Summary
MDWD Quant Ranking